Helin, Tuukka
(Helsingin yliopisto, 2017)
Direct oral anticoagulants (DOACs), the thrombin inhibitor dabigatran and the anti-Xa inhibitors rivaroxaban and apixaban are are simple to use as standard dosing is recommended and no routine monitoring of coagulation is advocated. However, in certain clinical situations, e.g. acute thrombosis or bleeding, emergency surgery and renal or hepatic failure, assessing anticoagulant bioactivity is essential.
The aims of this study were to firstly assess the effects of these DOACs in commonly used coagulation screening tests (PT, INR and APTT) using both spiked samples and samples collected from patients on treatment. Secondly, the availability of specific methods for drug effect assessment, namely drug-calibrated thrombin time (dabigatran) and anti-Xa (rivaroxaban, apixaban) assays were assessed in laboratory surveys. Thirdly, the effects of DOACs on these specific assays were explored using patient samples. Finally, the effect of DOACs on the global coagulation assay thrombin generation (TG) was assessed in patients using dabigatran, rivaroxaban or apixaban.
The spiked sample laboratory surveys included a total of 86 European laboratories. The effects of all DOACs on INR were modest, but large reagent variability was noted in the responses (p<0.001). In APTT, rivaroxaban and apixaban prolonged the APTT only modestly, but with dabigatran there was a clear prolongation. Only about a fourth of the laboratories were able to provide more specific methods, TT or anti-Xa assays for drug quantification.
Dabigatran effects in patient samples were studied 241 unselected patient samples. The PT was rarely prolonged and the APTT was in curvilinear relationship (R2 = 0.71) with dabigatran. However, the sensitivity effects among patients varied, with some patients having a normal APTT at dabigatran levels up to 160 ng/mL. Several specific assays, (diluted thrombin time, ecarin clotting assay and anti-IIa assay) accurately quantified dabigatran concentrations. In TG, a paradoxical increase was observed in the endogenous thrombin potential (ETP) and Peak TG, while lag time also prolonged with increasing concentrations of dabigatran.
Rivaroxaban and apixaban effects on coagulation in patient samples were further assessed in a well-characterised group of patients using these drugs for thromboprophylaxis after orthopaedic surgery. Rivaroxaban peak drug levels were higher and trough levels lower than with apixaban, reflecting the once daily vs twice daily dosing of the drugs. In TG, the ETP response at peak drug levels was strong with rivaroxaban, whereas with the trough drug levels, the TG parameters were close to the baseline levels. With apixaban the responses were more stable. The RVVT, used as a qualitative test, detected prolongation only at rivaroxaban peak levels.
In conclusion, DOACs present significant challenges in the clinical laboratory, as a wide variety of reagents are used in coagulation assays, and the drug responses also vary widely between individual patients. Many factors other than drug concentration influence the responses in coagulation assays and TG. In clinical practice, care and diligence is required when assessing the effects of DOACs on patients.